Yong-Ku Kim

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/332388/publications.pdf

Version: 2024-02-01

265 papers 13,639 citations

62 h-index 28296 105 g-index

266 all docs 266 docs citations

266 times ranked 14930 citing authors

#	Article	IF	CITATIONS
1	Possible oxytocin-related biomarkers in anxiety and mood disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2022, 116, 110531.	4.8	10
2	Associations between Melatonin, Neuroinflammation, and Brain Alterations in Depression. International Journal of Molecular Sciences, 2022, 23, 305.	4.1	37
3	Neural substrates for late-life depression: A selective review of structural neuroimaging studies. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 104, 110010.	4.8	37
4	Increased use of ketamine for the treatment of depression: Benefits and concerns. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 104, 110060.	4.8	11
5	An alternative approach to future diagnostic standards for major depressive disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 105, 110133.	4.8	10
6	Association between genetic variants of the norepinephrine transporter gene (SLC6A2) and bipolar I disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 107, 110227.	4.8	4
7	Inflammatory Biomarkers in AD: Implications for Diagnosis. Current Alzheimer Research, 2021, 17, 962-971.	1.4	6
8	Crosstalk between Depression and Dementia with Resting-State fMRI Studies and Its Relationship with Cognitive Functioning. Biomedicines, 2021, 9, 82.	3.2	23
9	Development of Neuroimaging-Based Biomarkers in Major Depression. Advances in Experimental Medicine and Biology, 2021, 1305, 85-99.	1.6	8
10	The Role of Neurotrophic Factors in Pathophysiology of Major Depressive Disorder. Advances in Experimental Medicine and Biology, 2021, 1305, 257-272.	1.6	16
11	Challenges and Strategies for Current Classifications of Depressive Disorders: Proposal for Future Diagnostic Standards. Advances in Experimental Medicine and Biology, 2021, 1305, 103-116.	1.6	11
12	Understanding the Connection Between the Gut–Brain Axis and Stress/Anxiety Disorders. Current Psychiatry Reports, 2021, 23, 22.	4.5	22
13	Gut Microbiota and Bipolar Disorder: An Overview on a Novel Biomarker for Diagnosis and Treatment. International Journal of Molecular Sciences, 2021, 22, 3723.	4.1	31
14	The Relationship between Plasma Erythropoietin Levels and Symptoms of Attention Deficit Hyperactivity Disorder. Clinical Psychopharmacology and Neuroscience, 2021, 19, 334-340.	2.0	3
15	Plasma level of brain-derived neurotrophic factor (BDNF) in patients with postpartum depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 109, 110245.	4.8	10
16	Variable alterations in plasma erythropoietin and brain-derived neurotrophic factor levels in patients with major depressive disorder with and without a history of suicide attempt. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 110, 110324.	4.8	5
17	Changes in Brain Electrical Activity According to Post-traumatic Stress Symptoms in Survivors of the Sewol Ferry Disaster: A 1-year Longitudinal Study. Clinical Psychopharmacology and Neuroscience, 2021, 19, 537-544.	2.0	2
18	Graph theory approach for the structural-functional brain connectome of depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 111, 110401.	4.8	47

#	Article	IF	CITATIONS
19	Recent advances and challenges in major depressive disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 111, 110403.	4.8	2
20	The Application of a Machine Learning-Based Brain Magnetic Resonance Imaging Approach in Major Depression. Advances in Experimental Medicine and Biology, 2021, 1305, 57-69.	1.6	4
21	EEG Correlates of Cognitive Functions and Neuropsychiatric Disorders: A Review of Oscillatory Activity and Neural Synchrony Abnormalities. Current Psychiatry Research and Reviews, 2021, 16, 228-243.	0.2	1
22	Grey matter volume abnormalities in the first depressive episode of medication-na \tilde{A}^- ve adult individuals: a systematic review of voxel based morphometric studies. International Journal of Psychiatry in Clinical Practice, 2021, 25, 407-420.	2.4	11
23	Neuroinflammation-Associated Alterations of the Brain as Potential Neural Biomarkers in Anxiety Disorders. International Journal of Molecular Sciences, 2020, 21, 6546.	4.1	48
24	The role of CREB and BDNF in neurobiology and treatment of Alzheimer's disease. Life Sciences, 2020, 257, 118020.	4.3	198
25	Immunomodulatory Effects of Antipsychotic Drugs in Whole Blood Cell Cultures from Healthy Subjects. Current Psychiatry Research and Reviews, 2020, 15, 261-266.	0.2	1
26	Predicting future onset of depression among community dwelling adults in the Republic of Korea using a machine learning algorithm. Neuroscience Letters, 2020, 721, 134804.	2.1	29
27	Neuron-to-microglia Crosstalk in Psychiatric Disorders. Current Neuropharmacology, 2020, 18, 84-86.	2.9	2
28	Serum FAM19A5 levels: A novel biomarker for neuroinflammation and neurodegeneration in major depressive disorder. Brain, Behavior, and Immunity, 2020, 87, 852-859.	4.1	27
29	Anxiety Disorders in the DSM-5: Changes, Controversies, and Future Directions. Advances in Experimental Medicine and Biology, 2020, 1191, 187-196.	1.6	22
30	Comorbid Anxiety and Depression: Clinical and Conceptual Consideration and Transdiagnostic Treatment. Advances in Experimental Medicine and Biology, 2020, 1191, 219-235.	1.6	121
31	Phenotype Network and Brain Structural Covariance Network of Anxiety. Advances in Experimental Medicine and Biology, 2020, 1191, 21-34.	1.6	4
32	The Role of the Oxytocin System in Anxiety Disorders. Advances in Experimental Medicine and Biology, 2020, 1191, 103-120.	1.6	42
33	An Update on Glutamatergic System in Suicidal Depression and on the Role of Esketamine. Current Topics in Medicinal Chemistry, 2020, 20, 554-584.	2.1	25
34	Major Depressive Disorder: Current Advances and Paradigm Shifts. Psychiatry Investigation, 2020, 17, 179-180.	1.6	3
35	Ketamine in Major Depressive Disorder: Mechanisms and Future Perspectives. Psychiatry Investigation, 2020, 17, 181-192.	1.6	22
36	A review on inflammatory cytokine-induced alterations of the brain as potential neural biomarkers in post-traumatic stress disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 91, 103-112.	4.8	59

#	Article	IF	CITATIONS
37	Usefulness of the 15-item geriatric depression scale (GDS-15) for classifying minor and major depressive disorders among community-dwelling elders. Journal of Affective Disorders, 2019, 259, 370-375.	4.1	70
38	The role of NMDA receptor in neurobiology and treatment of major depressive disorder: Evidence from translational research. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 94, 109668.	4.8	58
39	Autoimmunity in microbiome-mediated diseases and novel therapeutic approaches. Current Opinion in Pharmacology, 2019, 49, 34-42.	3.5	13
40	A Novel Bio-Psychosocial-Behavioral Treatment Model of Panic Disorder. Psychiatry Investigation, 2019, 16, 4-15.	1.6	9
41	Panic Disorder: Current Research and Management Approaches. Psychiatry Investigation, 2019, 16, 1-3.	1.6	5
42	The associations of TAC1 gene polymorphisms with major depressive disorder. Molecular and Cellular Toxicology, 2019, 15, 129-136.	1.7	1
43	Guidelines for the standardized collection of blood-based biomarkers in psychiatry: Steps for laboratory validity \hat{a} \in " a consensus of the Biomarkers Task Force from the WFSBP. World Journal of Biological Psychiatry, 2019, 20, 340-351.	2.6	20
44	Relationships between hand-grip strength, socioeconomic status, and depressive symptoms in community-dwelling older adults. Journal of Affective Disorders, 2019, 252, 263-270.	4.1	43
45	Biomarkers of Major Depression Related to Serotonin Receptors. Current Psychiatry Reviews, 2019, 14, 239-244.	0.9	8
46	Association of metabolic syndrome and its components with suicidal ideation and depression in adults: A nationally representative sample of the Korean population. Journal of Affective Disorders, 2019, 249, 319-326.	4.1	10
47	Intimate partner violence and incidence of depression in married women: A longitudinal study of a nationally representative sample. Journal of Affective Disorders, 2019, 245, 305-311.	4.1	11
48	Treatment-Resistant Depression: Understandings on the Neurobiological Etiology that Lead to Novel Pharmacological Treatment Options. , 2019, , 99-107.		0
49	Comorbid Sleep and Wake Problems in Treatment-Resistant Psychiatric Conditions. , 2019, , 261-270.		0
50	Integrated Approaches for Treatment-Resistant Psychiatric Disorders. , 2019, , 87-96.		1
51	Neuroendocrinological treatment targets for posttraumatic stress disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 90, 212-222.	4.8	13
52	Promising neural diagnostic biomarkers and predictors of treatment outcomes for psychiatric disorders: Novel neuroimaging approaches. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 91, 1-3.	4.8	3
53	Differentiating between bipolar and unipolar depression in functional and structural MRI studies. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 91, 20-27.	4.8	144
54	Interactive effects of genetic polymorphisms and childhood adversity on brain morphologic changes in depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 91, 4-13.	4.8	37

#	Article	IF	Citations
55	Big Data and Discovery Sciences in Psychiatry. Advances in Experimental Medicine and Biology, 2019, 1192, 3-15.	1.6	3
56	Classification of Psychiatric Disorders. Advances in Experimental Medicine and Biology, 2019, 1192, 17-25.	1.6	8
57	Role of Inflammation in Psychiatric Disorders. Advances in Experimental Medicine and Biology, 2019, 1192, 491-501.	1.6	8
58	The Frontiers of Suicide. Advances in Experimental Medicine and Biology, 2019, 1192, 503-517.	1.6	9
59	Neuromodulation and Cognitive Control of Emotion. Advances in Experimental Medicine and Biology, 2019, 1192, 545-564.	1.6	20
60	Cognitive Behavioral Therapy for Insomnia in the Digital Age. Advances in Experimental Medicine and Biology, 2019, 1192, 629-641.	1.6	8
61	Novel Pathways in the Treatment of Major Depression: Focus on the Glutamatergic System. Current Pharmaceutical Design, 2019, 25, 381-387.	1.9	33
62	Diagnostic Issues of Depressive Disorders from Kraepelinian Dualism to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Psychiatry Investigation, 2019, 16, 636-644.	1.6	13
63	Contemporary Issues in Depressive Disorders. Psychiatry Investigation, 2019, 16, 633-635.	1.6	8
64	An Integrated Bio-psycho-social Approach to Psychiatric Disorders. Advances in Experimental Medicine and Biology, 2019, 1192, 331-340.	1.6	6
65	The development of glutamate-based antidepressants is taking longer than expected. Drug Discovery Today, 2018, 23, 1689-1692.	6.4	12
66	Evidence for additionally increased apoptosis in the peripheral blood mononuclear cells of major depressive patients with a high risk for suicide. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2018, 177, 388-396.	1.7	11
67	The effects of 5-HTTLPR and BDNF Val66Met polymorphisms on neurostructural changes in major depressive disorder. Psychiatry Research - Neuroimaging, 2018, 273, 25-34.	1.8	35
68	Effectiveness of memantine on depression-like behavior, memory deficits and brain mRNA levels of BDNF and TrkB in rats subjected to repeated unpredictable stress. Pharmacological Reports, 2018, 70, 600-606.	3.3	28
69	Tinnitus, depression, and suicidal ideation in adults: A nationally representative general population sample. Journal of Psychiatric Research, 2018, 98, 124-132.	3.1	34
70	Depression in DSM-5: Changes, Controversies, and Future Directions., 2018,, 3-14.		6
71	Is a Combination of Pharmacotherapy and Psychotherapy Superior to Each Alone?., 2018,, 289-303.		2
72	Pathophysiology and Treatment Strategies for Different Types of Depression. , 2018, , 167-176.		O

#	Article	IF	Citations
73	Imaging Genetics Studies on Susceptibility Genes for Major Depressive Disorder, the Present and the Future., 2018,, 17-39.		O
74	Emerging Role of Glutamate Receptors in Pathophysiology of Depression., 2018,, 97-105.		0
75	Differential effect of COMT gene methylation on the prefrontal connectivity in subjects with depression versus healthy subjects. Neuropharmacology, 2018, 137, 59-70.	4.1	41
76	The role of memantine in the treatment of major depressive disorder: Clinical efficacy and mechanisms of action. European Journal of Pharmacology, 2018, 827, 103-111.	3.5	35
77	Application of machine learning classification for structural brain MRI in mood disorders: Critical review from a clinical perspective. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 80, 71-80.	4.8	80
78	Common and distinct brain networks underlying panic and social anxiety disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 80, 115-122.	4.8	59
79	Neuroimaging in psychiatry: Steps toward the clinical application of brain imaging in psychiatric disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 80, 69-70.	4.8	4
80	Sickness absence indicating depressive symptoms of working population in South Korea. Journal of Affective Disorders, 2018, 227, 443-449.	4.1	2
81	Rapid-Acting Antidepressant Effect of Ketamine and Its Clinical Application. Journal of Korean Neuropsychiatric Association, 2018, 57, 108.	0.5	0
82	Preface: Paradigm Shift in Depression Research. Current Psychiatry Reviews, 2018, 14, 2-2.	0.9	0
83	Application of Assessment Tools to Examine Mental Health in Workplaces: Job Stress and Depression. Psychiatry Investigation, 2018, 15, 553-560.	1.6	10
84	Interaction effects of oxytocin receptor gene polymorphism and depression on hippocampal volume. Psychiatry Research - Neuroimaging, 2018, 282, 18-23.	1.8	19
85	196G/A of the Brain-Derived Neurotrophic Factor Gene Polymorphisms Predicts Suicidal Behavior in Schizophrenia Patients. Psychiatry Investigation, 2018, 15, 733-738.	1.6	14
86	Emotional labor and depressive mood in service and sales workers: Interactions with gender and job autonomy. Psychiatry Research, 2018, 267, 490-498.	3.3	25
87	The role of neuroinflammation and neurovascular dysfunction in major depressive disorder. Journal of Inflammation Research, 2018, Volume 11, 179-192.	3.5	83
88	Relationship of depression, chronic disease, self-rated health, and gender with health care utilization among community-living elderly. Journal of Affective Disorders, 2018, 241, 402-410.	4.1	39
89	The identification of biomarkers predicting acute and maintenance lithium treatment response in bipolar disorder: A plea for further research attention. Psychiatry Research, 2018, 269, 658-672.	3.3	21
90	Editorial: Glia-Neuron Crosstalk and its Therapeutic Implication in Neuropsychiatric Disorders. Current Neuropharmacology, 2018, 16, 506-507.	2.9	0

#	Article	IF	Citations
91	Recent Developments on Future Antidepressant-related Serotonin Receptors. Current Pharmaceutical Design, 2018, 24, 2541-2548.	1.9	15
92	Neuroinflammation and the Immune-Kynurenine Pathway in Anxiety Disorders. Current Neuropharmacology, 2018, 16, 574-582.	2.9	86
93	The Microbiota-Gut-Brain Axis in Neuropsychiatric Disorders: Pathophysiological Mechanisms and Novel Treatments. Current Neuropharmacology, 2018, 16, 559-573.	2.9	147
94	Natural Course of Posttraumatic Symptoms in Late-Adolescent Maritime Disaster Survivors: Results of A 12-Month Follow-Up Study. Psychiatry Investigation, 2018, 15, 574-583.	1.6	4
95	Panic disorders: The role of genetics and epigenetics. AIMS Genetics, 2018, 05, 177-190.	1.9	12
96	Meet Our Editor-in-Chief. Current Psychiatry Reviews, 2018, 14, 1-1.	0.9	0
97	Influence of FKBP5 polymorphism and DNA methylation on structural changes of the brain in major depressive disorder. Scientific Reports, 2017, 7, 42621.	3.3	74
98	Increased levels of 5HT2A receptor mRNA expression in peripheral blood mononuclear cells of patients with major depression: correlations with severity and duration of illness. Nordic Journal of Psychiatry, 2017, 71, 282-288.	1.3	26
99	The influence of stress on neuroinflammation and alterations in brain structure and function in major depressive disorder. Behavioural Brain Research, 2017, 329, 6-11.	2.2	125
100	Association of norepinephrine transporter gene polymorphisms in attention-deficit/hyperactivity disorder in Korean population. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2017, 73, 56-63.	4.8	6
101	The association between substance P and white matter integrity in medication-naive patients with major depressive disorder. Scientific Reports, 2017, 7, 9707.	3.3	11
102	Inflammation-induced depression: Its pathophysiology and therapeutic implications. Journal of Neuroimmunology, 2017, 313, 92-98.	2.3	105
103	Effect of co-administration of memantine and sertraline on the antidepressant-like activity and brain-derived neurotrophic factor (BDNF) levels in the rat brain. Brain Research Bulletin, 2017, 128, 29-33.	3.0	28
104	Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia, part III: Molecular mechanisms. World Journal of Biological Psychiatry, 2017, 18, 330-356.	2.6	33
105	Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition. World Journal of Biological Psychiatry, 2017, 18, 162-214.	2.6	226
106	Unresolved Issues for Utilization of Atypical Antipsychotics in Schizophrenia: Antipsychotic Polypharmacy and Metabolic Syndrome. International Journal of Molecular Sciences, 2017, 18, 2174.	4.1	62
107	An Oldie but Goodie: Lithium in the Treatment of Bipolar Disorder through Neuroprotective and Neurotrophic Mechanisms. International Journal of Molecular Sciences, 2017, 18, 2679.	4.1	139
108	A Novel Bio-Psychosocial-Behavioral Treatment Model in Schizophrenia. International Journal of Molecular Sciences, 2017, 18, 734.	4.1	15

7

#	Article	IF	Citations
109	Correlation of occupational stress with depression, anxiety, and sleep in Korean dentists: cross-sectional study. BMC Psychiatry, 2017, 17, 398.	2.6	47
110	Eye Movement Desensitization and Reprocessing to Facilitate Posttraumatic Growth: A Prospective Clinical Pilot Study on Ferry Disaster Survivors. Clinical Psychopharmacology and Neuroscience, 2017, 15, 320-327.	2.0	8
111	Prevalence and Associated Factors of Depression in General Population of Korea: Results from the Korea National Health and Nutrition Examination Survey, 2014. Journal of Korean Medical Science, 2017, 32, 1861.	2.5	101
112	Neuroprotection in Schizophrenia and Its Therapeutic Implications. Psychiatry Investigation, 2017, 14, 383.	1.6	18
113	Neuroinflammation and cytokine abnormality in major depression: Cause or consequence in that illness?. World Journal of Psychiatry, 2016, 6, 283.	2.7	161
114	Do Somatic Symptoms Predict the Severity of Depression? A Validation Study of the Korean Version of the Depression and Somatic Symptoms Scale. Journal of Korean Medical Science, 2016, 31, 2002.	2.5	9
115	Stress, the Autonomic Nervous System, and the Immune-kynurenine Pathway in the Etiology of Depression. Current Neuropharmacology, 2016, 14, 665-673.	2.9	183
116	Molecular Neurobiology and Promising New Treatment in Depression. International Journal of Molecular Sciences, 2016, 17, 381.	4.1	52
117	The G allele in IL-10-1082 G/A may have a role in lowering the susceptibility to panic disorder in female patients. Acta Neuropsychiatrica, 2016, 28, 357-361.	2.1	4
118	Role of glutamate receptors and glial cells in the pathophysiology of treatment-resistant depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2016, 70, 117-126.	4.8	52
119	Plasma glial cell line-derived neurotrophic factor in patients with major depressive disorder: a preliminary study. Acta Neuropsychiatrica, 2016, 28, 45-50.	2.1	11
120	Plasticity-augmented psychotherapy for refractory depressive and anxiety disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2016, 70, 134-147.	4.8	8
121	Clinical and neurobiological factors in the management of treatment refractory attention-deficit hyperactivity disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2016, 70, 237-244.	4.8	21
122	Can we cope with treatment refractoriness in psychiatric disorders?. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2016, 70, 101-102.	4.8	2
123	Brain-derived neurotrophic factor promoter methylation and cortical thickness in recurrent major depressive disorder. Scientific Reports, 2016, 6, 21089.	3.3	71
124	Second-to-fourth digit length ratio as a measure of harm avoidance. Personality and Individual Differences, 2016, 97, 30-34.	2.9	1
125	The role of pro-inflammatory cytokines in neuroinflammation, neurogenesis and the neuroendocrine system in major depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2016, 64, 277-284.	4.8	448
126	Molecular neurobiology of major depressive disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2016, 64, 275-276.	4.8	9

#	Article	IF	Citations
127	Biochemical Markers., 2016, , 155-176.		2
128	Decreased Plasma BDNF Levels of Patients with Somatization Disorder. Psychiatry Investigation, 2016, 13, 526.	1.6	7
129	Association Study between Norepinephrine Transporter Gene Polymorphism and Schizophrenia in a Korean Population. Psychiatry Investigation, 2015, 12, 551.	1.6	4
130	Alterations in plasma vascular endothelial growth factor levels in patients with schizophrenia before and after treatment. Psychiatry Research, 2015, 228, 95-99.	3.3	38
131	Increased levels of plasma glial-derived neurotrophic factor in children with attention deficit hyperactivity disorder. Nordic Journal of Psychiatry, 2015, 69, 546-551.	1.3	24
132	Cognitive Impairment in Depression. Current Psychiatry Reviews, 2015, 11, 280-289.	0.9	2
133	The role of immunity and neuroinflammation in genetic predisposition and pathogenesis of Alzheimer's disease. AlMS Genetics, 2015, 02, 230-249.	1.9	2
134	Evidence for Association between the Brain-Derived Neurotrophic Factor Gene and Panic Disorder: A Novel Haplotype Analysis. Psychiatry Investigation, 2015, 12, 112.	1.6	22
135	Possible Association between Serotonin Transporter Gene Polymorphism and Suicide Behavior in Major Depressive Disorder. Psychiatry Investigation, 2015, 12, 136.	1.6	13
136	Alteration of Brain-Derived Neurotrophic Factor Levels in Panic Disorder. Journal of Korean Neuropsychiatric Association, 2015, 54, 482.	0.5	1
137	There is no association between the serotonin receptor gene and bipolar I disorder in the Korean population. Nordic Journal of Psychiatry, 2014, 68, 488-493.	1.3	3
138	The role of pro-inflammatory cytokines in the neuroinflammation and neurogenesis of schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2014, 48, 277-286.	4.8	304
139	Network beyond IDO in psychiatric disorders: Revisiting neurodegeneration hypothesis. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2014, 48, 304-313.	4.8	184
140	Usefulness of the Patient Health Questionnaire-9 for Korean Medical Students. Academic Psychiatry, 2014, 38, 661-667.	0.9	28
141	Association between norepinephrine transporter gene (SLC6A2) polymorphisms and suicide in patients with major depressive disorder. Journal of Affective Disorders, 2014, 158, 127-132.	4.1	16
142	Association between Glucocorticoid Receptor Methylation and Hippocampal Subfields in Major Depressive Disorder. PLoS ONE, 2014, 9, e85425.	2.5	125
143	High insulin-like growth factor-1 in patients with bipolar I disorder: A trait marker?. Journal of Affective Disorders, 2013, 151, 738-743.	4.1	34
144	Decreased gray matter volume of the medial orbitofrontal cortex in panic disorder with agoraphobia: A preliminary study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2013, 45, 195-200.	4.8	25

#	Article	IF	CITATIONS
145	Alexithymia and low cooperativeness are associated with suicide attempts in male military personnel with adjustment disorder: A case–control study. Psychiatry Research, 2013, 205, 220-226.	3.3	24
146	TNF-alpha â^'308G>A polymorphism is associated with suicide attempts in major depressive disorder. Journal of Affective Disorders, 2013, 150, 668-672.	4.1	36
147	Distinguishing Quantitative Electroencephalogram Findings between Adjustment Disorder and Major Depressive Disorder. Psychiatry Investigation, 2013, 10, 62.	1.6	20
148	Anti-Intrusion Effect of Lorazepam: An Experimental Study. Psychiatry Investigation, 2013, 10, 273.	1.6	5
149	Plasma Levels of IL-23 and IL-17 before and after Antidepressant Treatment in Patients with Major Depressive Disorder. Psychiatry Investigation, 2013, 10, 294.	1.6	56
150	Role of cytokines in atypical depression. Nordic Journal of Psychiatry, 2012, 66, 183-188.	1.3	51
151	Temperament and Character of Young Male Conscripts With Adjustment Disorder. Journal of Nervous and Mental Disease, 2012, 200, 973-977.	1.0	10
152	The T allele of the interferon-gamma +874A/T polymorphism is associated with bipolar disorder. Nordic Journal of Psychiatry, 2012, 66, 14-18.	1.3	15
153	Bright light therapy as an adjunctive treatment with risperidone in patients with delirium: a randomized, open, parallel group study. General Hospital Psychiatry, 2012, 34, 546-551.	2.4	31
154	Association between glycogen synthase kinase- $3\hat{l}^2$ gene polymorphisms and attention deficit hyperactivity disorder in Korean children: A preliminary study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2012, 39, 57-61.	4.8	4
155	Characteristics of Type D personality in Korean adolescents. European Child and Adolescent Psychiatry, 2012, 21, 699-706.	4.7	9
156	A Case of Blonanserin-Induced Mania in Schizophrenia. Korean Journal of Schizophrenia Research, 2012, 15, 46.	0.3	0
157	State Effect of Traumatic Experience on Personality Structure. Psychiatry Investigation, 2012, 9, 361.	1.6	4
158	Increased plasma VEGF levels in major depressive or manic episodes in patients with mood disorders. Journal of Affective Disorders, 2012, 136, 181-184.	4.1	77
159	Gasification and power generation characteristics of rice husk and rice husk pellet using a downdraft fixed-bed gasifier. Renewable Energy, 2012, 42, 163-167.	8.9	186
160	No Association between PAWR Gene Polymorphisms and Tardive Dyskinesia in Schizophrenia Patients. Psychiatry Investigation, 2012, 9, 191.	1.6	8
161	Standardization of the Korean Version of the Posttraumatic Embitterment Disorder Self-Rating Scale. Psychiatry Investigation, 2012, 9, 368.	1.6	23
162	Reversal of imbalance between kynurenic acid and 3-hydroxykynurenine by antipsychotics in medication-naÃ-ve and medication-free schizophrenic patients. Brain, Behavior, and Immunity, 2011, 25, 1576-1581.	4.1	110

#	Article	IF	CITATIONS
163	Suicide and suicidal behavior. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 795.	4.8	O
164	The impact of glycogen synthase kinase $3\hat{l}^2$ gene on psychotic mania in bipolar disorder patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 1303-1308.	4.8	14
165	Adjunctive treatment of bimodal repetitive transcranial magnetic stimulation (rTMS) in pharmacologically non-responsive patients with schizophrenia: A preliminary study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 1938-1943.	4.8	16
166	Potential peripheral biological predictors of suicidal behavior in major depressive disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 842-847.	4.8	77
167	Assessment of the Type D Personality Construct in the Korean Population: A Validation Study of the Korean DS14. Journal of Korean Medical Science, 2011, 26, 116.	2.5	101
168	Paliperidone in the treatment of delirium: results of a prospective open-label pilot trial. Acta Neuropsychiatrica, 2011, 23, 179-183.	2.1	8
169	Effect of Serotonin-Related Gene Polymorphisms on Pathogenesis and Treatment Response in Korean Schizophrenic Patients. Behavior Genetics, 2011, 41, 709-715.	2.1	19
170	Gender Effect of Catechol- <i>O</i> -Methyltransferase Val158Met Polymorphism on Suicidal Behavior. Neuropsychobiology, 2011, 63, 177-182.	1.9	10
171	The Mediating Effect of Psychosocial Factors on Suicidal Probability among Adolescents. Archives of Suicide Research, 2011, 15, 327-336.	2.3	11
172	No Evidence for an Association between Dopamine D2 Receptor Polymorphisms and Tardive Dyskinesia in Korean Schizophrenia Patients. Psychiatry Investigation, 2011, 8, 49.	1.6	18
173	Borna Disease Virus Antibody and RNA from Peripheral Blood Mononuclear Cells of Race Horses and Jockeys in Korea. Psychiatry Investigation, 2011, 8, 58.	1.6	4
174	Efficacy and Tolerability of Blonanserin in the Patients With Schizophrenia. Clinical Neuropharmacology, 2010, 33, 169-175.	0.7	211
175	Psychotropic Drugs on In Vitro Brain-Derived Neurotrophic Factor Production in Whole Blood Cell Cultures From Healthy Subjects. Journal of Clinical Psychopharmacology, 2010, 30, 623-627.	1.4	7
176	BDNF mRNA expression of peripheral blood mononuclear cells was decreased in depressive patients who had or had not recently attempted suicide. Journal of Affective Disorders, 2010, 125, 369-373.	4.1	56
177	Association study between antipsychoticâ€induced restless legs syndrome and polymorphisms of monoamine oxidase genes in schizophrenia. Human Psychopharmacology, 2010, 25, 397-403.	1.5	22
178	Effect of TGF- $\langle i \rangle \hat{l}^2 \langle i \rangle 1$ polymorphism on the susceptibility to schizophrenia and treatment response to atypical antipsychotic agent. Acta Neuropsychiatrica, 2010, 22, 174-179.	2.1	4
179	The Roles of BDNF in the Pathophysiology of Major Depression and in Antidepressant Treatment. Psychiatry Investigation, 2010, 7, 231.	1.6	364
180	Brain-derived neurotrophic factor gene polymorphisms and mirtazapine responses in Koreans with major depression. Journal of Psychopharmacology, 2010, 24, 1755-1763.	4.0	45

#	Article	IF	CITATIONS
181	BDNF MRNA EXPRESSION OF PERIPHERAL BLOOD MONONUCLEAR CELLS WAS DECREASED IN PATIENTS WITH SCHIZOPHRENIA. Schizophrenia Research, 2010, 117, 369.	2.0	1
182	Association between glycogen synthase kinase- $3\hat{l}^2$ gene polymorphisms and major depression and suicidal behavior in a Korean population. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 331-334.	4.8	15
183	A case-control association study of serotonin 1A receptor gene and tryptophan hydroxylase 2 gene in attention deficit hyperactivity disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 974-979.	4.8	18
184	Catechol-O-methyltransferase Val158Met polymorphism affects therapeutic response to mood stabilizer in symptomatic manic patients. Psychiatry Research, 2010, 175, 63-66.	3.3	26
185	Transforming growth factor- \hat{l}^21 and major depressive disorder with and without attempted suicide: Preliminary study. Psychiatry Research, 2010, 178, 92-96.	3.3	26
186	Association between Serotonin-Related Polymorphisms in 5HT2A, TPH1, TPH2 Genes and Bipolar Disorder in Korean Population. Psychiatry Investigation, 2010, 7, 60.	1.6	17
187	Association Study between 5-HT1A Receptor Gene C(-1019)G Polymorphism and Panic Disorder in a Korean Population. Psychiatry Investigation, 2010, 7, 141.	1.6	21
188	Increased Transforming Growth Factor-beta1 in Alcohol Dependence. Journal of Korean Medical Science, 2009, 24, 941.	2.5	16
189	Increased Plasma Brain-Derived Neurotropic Factor, Not Nerve Growth Factor-Beta, in Schizophrenia Patients with Better Response to Risperidone Treatment. Neuropsychobiology, 2009, 59, 51-58.	1.9	61
190	Cytokine Changes and Tryptophan Metabolites in Medication-NaÃ-ve and Medication-Free Schizophrenic Patients. Neuropsychobiology, 2009, 59, 123-129.	1.9	122
191	A Tryptophan Hydroxylase 2 Gene Polymorphism is Associated with Panic Disorder. Behavior Genetics, 2009, 39, 170-175.	2.1	64
192	Relation between plasma brain-derived neurotrophic factor and nerve growth factor in the male patients with alcohol dependence. Alcohol, 2009, 43, 265-269.	1.7	50
193	No association of serotonin transporter polymorphism (5-HTTVNTR and 5-HTTLPR) with characteristics and treatment response to atypical antipsychotic agents in schizophrenic patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2009, 33, 276-280.	4.8	20
194	TPH2 -703G/T SNP may have important effect on susceptibility to suicidal behavior in major depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2009, 33, 403-409.	4.8	66
195	Reduced platelet BDNF level in patients with major depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2009, 33, 849-853.	4.8	98
196	Schizophrenia: From the brain to peripheral markers. A consensus paper of the WFSBP task force on biological markers. World Journal of Biological Psychiatry, 2009, 10, 127-155.	2.6	64
197	Comparison of Clinical Features and Personality Dimensions between Patients with Major Depressive Disorder and Normal Control. Psychiatry Investigation, 2009, 6, 150.	1.6	30
198	Failure to Detect Borna Disease Virus Antibody and RNA from Peripheral Blood Mononuclear Cells of Psychiatric Patients. Psychiatry Investigation, 2009, 6, 306.	1.6	23

#	Article	IF	CITATIONS
199	Prediction of postpartum depression by sociodemographic, obstetric and psychological factors: A prospective study. Psychiatry and Clinical Neurosciences, 2008, 62, 331-340.	1.8	48
200	A single administration of 2,3,7,8-tetrachlorodibenzo-p-dioxin that produces reduced food and water intake induces long-lasting expression of corticotropin-releasing factor, arginine vasopressin, and proopiomelanocortin in rat brain. Toxicology and Applied Pharmacology, 2008, 233, 314-322.	2.8	15
201	Reduced plasma nitric oxide metabolites before and after antipsychotic treatment in patients with schizophrenia compared to controls. Schizophrenia Research, 2008, 104, 36-43.	2.0	44
202	The association between serotonin-related gene polymorphisms and panic disorder. Journal of Anxiety Disorders, 2008, 22, 1529-1534.	3.2	45
203	Possible association between the â^2548A/G polymorphism of the leptin gene and olanzapine-induced weight gain. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 160-163.	4.8	50
204	Differences in cytokines between non-suicidal patients and suicidal patients in major depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 356-361.	4.8	114
205	Association between serotonin-related gene polymorphisms and suicidal behavior in depressive patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 1293-1297.	4.8	18
206	No association between the brain-derived neurotrophic factor gene Val66Met polymorphism and tardive dyskinesia in schizophrenic patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 1545-1548.	4.8	23
207	Increased levels of plasma brain-derived neurotrophic factor (BDNF) in children with attention deficit-hyperactivity disorder (ADHD). Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 1824-1828.	4.8	105
208	Manganese superoxide dismutase gene Ala–9Val polymorphism might be related to the severity of abnormal involuntary movements in Korean schizophrenic patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 1844-1847.	4.8	28
209	ORIGINAL RESEARCHâ€"PHYSIOLOGY: Assessment of Cerebrocortical Areas Associated with Sexual Arousal in Depressive Women Using Functional MR Imaging. Journal of Sexual Medicine, 2008, 5, 602-609.	0.6	46
210	Val 158Met Polymorphism in the Catechol- <i>O</i> -Methyltransferase (<i>COMT)</i> Gene Is Not Associated with Tardive Dyskinesia in Schizophrenia. Neuropsychobiology, 2008, 57, 22-25.	1.9	18
211	Association Study between Antipsychotics- Induced Restless Legs Syndrome and Polymorphisms of Dopamine D1, D2, D3, and D4 Receptor Genes in Schizophrenia. Neuropsychobiology, 2008, 57, 49-54.	1.9	24
212	Plasma Brain-Derived Neurotrophic Factor as a Peripheral Marker for the Action Mechanism of Antidepressants. Neuropsychobiology, 2008, 57, 194-199.	1.9	116
213	Gender Differences in Suicidal Behavior in Korea. Psychiatry Investigation, 2008, 5, 28.	1.6	16
214	Cognitive Factors for Predicting Treatment Response in Schizophrenic Patients: One-Year Follow-Up Study. Psychiatry Investigation, 2008, 5, 106.	1.6	9
215	Effect of the COX-2 Inhibitor Celecoxib on Behavioural and Immune Changes in an Olfactory Bulbectomised Rat Model of Depression. NeuroImmunoModulation, 2007, 14, 65-71.	1.8	97
216	Monocytic, Th1 and Th2 Cytokine Alterations in the Pathophysiology of Schizophrenia. Neuropsychobiology, 2007, 56, 55-63.	1.9	68

#	Article	IF	Citations
217	No Association between Dopamine D4 Receptor Gene –521 C/T Polymorphism and Tardive Dyskinesia in Schizophrenia. Neuropsychobiology, 2007, 55, 47-51.	1.9	26
218	The five-factor gambling motivation model. Psychiatry Research, 2007, 150, 21-32.	3.3	163
219	Low plasma BDNF is associated with suicidal behavior in major depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 78-85.	4.8	248
220	Reply to Comments on "Low Plasma BDNF is associated with Suicidal Behavior in Major Depressionâ€, Progress in Neuro-Psychopharmacology and Biological Psychiatry 2006. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 580-581.	4.8	0
221	Cytokine imbalance in the pathophysiology of major depressive disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 1044-1053.	4.8	258
222	Characteristics and clinical correlates of restless legs syndrome in schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 1078-1083.	4.8	58
223	Increased plasma brain-derived neurotrophic factor levels in chronic smokers following unaided smoking cessation. Neuroscience Letters, 2007, 423, 53-57.	2.1	75
224	Decreased Plasma Brainâ€Derived Neurotrophic Factor Levels in Patients With Alcohol Dependence. Alcoholism: Clinical and Experimental Research, 2007, 31, 1833-1838.	2.4	112
225	Possible association between G-protein \hat{l}^2 3 subunit C825T polymorphism and antipsychotic-induced restless legs syndrome in schizophrenia. Acta Neuropsychiatrica, 2007, 19, 351-356.	2.1	12
226	Kynurenine pathway in major depression: Evidence of impaired neuroprotection. Journal of Affective Disorders, 2007, 98, 143-151.	4.1	470
227	Decreased plasma BDNF level in depressive patients. Journal of Affective Disorders, 2007, 101, 239-244.	4.1	281
228	Tryptophan breakdown pathway in bipolar mania. Journal of Affective Disorders, 2007, 102, 65-72.	4.1	98
229	Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder. Journal of Affective Disorders, 2007, 104, 91-95.	4.1	334
230	Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: A pilot study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2006, 30, 714-717.	4.8	61
231	The role of IL-12 and TGF- \hat{l}^21 in the pathophysiology of major depressive disorder. International Immunopharmacology, 2006, 6, 1298-1304.	3.8	126
232	The relationship between prolactin response and clinical efficacy of risperidone in acute psychotic inpatients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2006, 30, 658-662.	4.8	39
233	Increased plasma nitric oxide level associated with suicide attempt in depressive patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2006, 30, 1091-1096.	4.8	93
234	Possible Role of Nerve Growth Factor in the Pathogenesis of Alcohol Dependence. Alcoholism: Clinical and Experimental Research, 2006, 30, 1060-1065.	2.4	26

#	Article	IF	CITATIONS
235	No borna disease virus-specific RNA detected in blood of race horses and jockeys. Acta Neuropsychiatrica, 2006, 18, 177-180.	2.1	2
236	Increased Plasma Nitric Oxide Metabolites in Suicide Attempters. Neuropsychobiology, 2006, 53, 127-132.	1.9	74
237	Antipsychotics and dopamine transporter gene polymorphisms in delirium patients. Psychiatry and Clinical Neurosciences, 2005, 59, 183-188.	1.8	42
238	Th1, Th2, and Th3 cytokine alterations in major depression. Journal of Affective Disorders, 2005, 88, 167-173.	4.1	287
239	Influence of the serotonin transporter promoter gene polymorphism on susceptibility to posttraumatic stress disorder. Depression and Anxiety, 2005, 21, 135-139.	4.1	214
240	INCREASED FASTING PLASMA GHRELIN LEVELS DURING ALCOHOL ABSTINENCE. Alcohol and Alcoholism, 2005, 40, 76-79.	1.6	122
241	The Role of Cytokine Network in the Pathophysiology of Schizophrenia. Current Psychiatry Reviews, 2005, 1, 123-131.	0.9	4
242	G-Protein \hat{l}^2 < sub>3 < /sub> Subunit C825T Polymorphism Tends to Be Associated with Seasonal Variation in Young Male College Students. Neuropsychobiology, 2005, 52, 135-139.	1.9	19
243	Treatment in risperidone-induced amenorrhoea. International Journal of Psychiatry in Clinical Practice, 2005, 9, 29-34.	2.4	7
244	High concentrations of plasma brain-derived neurotrophic factor in methamphetamine users. Neuroscience Letters, 2005, 388, 112-115.	2.1	82
245	Effects of serotonin and serotonergic agonists and antagonists on the production of tumor necrosis factor \hat{l}_{\pm} and interleukin-6. Psychiatry Research, 2005, 134, 251-258.	3.3	128
246	The Effects of Antidepressant Treatment on Serum Cytokines and Nutritional Status in Hemodialysis Patients. Journal of Korean Medical Science, 2004, 19, 384.	2.5	50
247	Auditory Event-Related Potentials and Psychological Changes during Sleep Deprivation. Neuropsychobiology, 2004, 50, 1-5.	1.9	47
248	Abnormal speech perception in schizophrenia with auditory hallucinations. Acta Neuropsychiatrica, 2004, 16, 154-159.	2.1	18
249	Clinical application of low serum cholesterol as an indicator for suicide risk in major depression. Journal of Affective Disorders, 2004, 81, 161-166.	4.1	84
250	Th1, Th2 and Th3 cytokine alteration in schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2004, 28, 1129-1134.	4.8	164
251	T-helper types 1, 2, and 3 cytokine interactions in symptomatic manic patients. Psychiatry Research, 2004, 129, 267-272.	3.3	90
252	Neurocognitive function and quality of life in relation to hematocrit levels in chronic hemodialysis patients. Journal of Psychosomatic Research, 2004, 57, 5-10.	2.6	49

#	Article	IF	CITATIONS
253	A Double-Blind Trial of Risperidone and Haloperidol for the Treatment of Delirium. Psychosomatics, 2004, 45, 297-301.	2.5	249
254	Allelic variants interaction of dopamine receptor D4 polymorphism correlate with personality traits in young Korean female population. American Journal of Medical Genetics Part A, 2003, 118B, 76-80.	2.4	33
255	Effects of alcohol hangover on cytokine production in healthy subjects. Alcohol, 2003, 31, 167-170.	1.7	78
256	Serum lipid levels and suicide attempts. Acta Psychiatrica Scandinavica, 2003, 108, 215-221.	4.5	59
257	The role of the cytokine network in psychological stress. Acta Neuropsychiatrica, 2003, 15, 148-155.	2.1	71
258	Borna disease virus and deficit schizophrenia. Acta Neuropsychiatrica, 2003, 15, 262-265.	2.1	7
259	Cytokine–serotonin interaction through IDO: a neurodegeneration hypothesis of depression. Medical Hypotheses, 2003, 61, 519-525.	1.5	360
260	Low serum cholesterol is correlated to suicidality in a Korean sample. Acta Psychiatrica Scandinavica, 2002, 105, 141-148.	4.5	63
261	Effect of Risperidone on Serum Cytokines. International Journal of Neuroscience, 2001, 111, 11-19.	1.6	48
262	Psychiatric Symptoms Reported by International Peacekeeping Personnel in the Western Sahara Desert. Journal of Nervous and Mental Disease, 2001, 189, 858-860.	1.0	33
263	Relationships between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics. Schizophrenia Research, 2000, 44, 165-175.	2.0	156
264	Risperidone and Associated Amenorrhea. Journal of Clinical Psychiatry, 1999, 60, 315-317.	2.2	38
265	Biological Markers and Genetic Factors of Major Depressive Disorder. , 0, , .		O